AKRO
Price
$27.34
Change
+$0.38 (+1.41%)
Updated
Sep 19, 09:54 AM (EDT)
55 days until earnings call
PHAT
Price
$19.00
Change
-$0.23 (-1.20%)
Updated
Sep 19, 10:42 AM (EDT)
48 days until earnings call
Ad is loading...

AKRO vs PHAT

Header iconAKRO vs PHAT Comparison
Open Charts AKRO vs PHATBanner chart's image
Akero Therapeutics
Price$27.34
Change+$0.38 (+1.41%)
Volume$100
CapitalizationN/A
Phathom Pharmaceuticals
Price$19.00
Change-$0.23 (-1.20%)
Volume$5.86K
CapitalizationN/A
View a ticker or compare two or three
AKRO vs PHAT Comparison Chart
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PHAT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
AKRO vs. PHAT commentary
Sep 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Hold and PHAT is a Hold.

COMPARISON
Comparison
Sep 19, 2024
Stock price -- (AKRO: $26.96 vs. PHAT: $19.25)
Brand notoriety: AKRO and PHAT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 91% vs. PHAT: 133%
Market capitalization -- AKRO: $1.85B vs. PHAT: $1.31B
AKRO [@Biotechnology] is valued at $1.85B. PHAT’s [@Biotechnology] market capitalization is $1.31B. The market cap for tickers in the [@Biotechnology] industry ranges from $599.73B to $0. The average market capitalization across the [@Biotechnology] industry is $3.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 1 FA rating(s) are green whilePHAT’s FA Score has 0 green FA rating(s).

  • AKRO’s FA Score: 1 green, 4 red.
  • PHAT’s FA Score: 0 green, 5 red.
According to our system of comparison, AKRO is a better buy in the long-term than PHAT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 7 TA indicator(s) are bullish while PHAT’s TA Score has 2 bullish TA indicator(s).

  • AKRO’s TA Score: 7 bullish, 2 bearish.
  • PHAT’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, AKRO is a better buy in the short-term than PHAT.

Price Growth

AKRO (@Biotechnology) experienced а +5.23% price change this week, while PHAT (@Biotechnology) price change was +2.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.81%. For the same industry, the average monthly price growth was +7.77%, and the average quarterly price growth was +2.01%.

Reported Earning Dates

AKRO is expected to report earnings on Nov 13, 2024.

PHAT is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (+7.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKRO($1.85B) has a higher market cap than PHAT($1.32B). PHAT YTD gains are higher at: 110.843 vs. AKRO (15.460). AKRO has higher annual earnings (EBITDA): -200.16M vs. PHAT (-238.33M). AKRO has more cash in the bank: 760M vs. PHAT (276M). AKRO has less debt than PHAT: AKRO (36.3M) vs PHAT (175M). PHAT has higher revenues than AKRO: PHAT (9.92M) vs AKRO (0).
AKROPHATAKRO / PHAT
Capitalization1.85B1.32B141%
EBITDA-200.16M-238.33M84%
Gain YTD15.460110.84314%
P/E RatioN/AN/A-
Revenue09.92M-
Total Cash760M276M275%
Total Debt36.3M175M21%
TECHNICAL ANALYSIS
Technical Analysis
AKROPHAT
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
N/A
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 8 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 11 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Ad is loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PHAT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LADSX21.550.05
+0.23%
Lord Abbett Developing Growth R4
MKLOX19.52N/A
N/A
BlackRock Global Allocation K
IJEAX11.57-0.02
-0.17%
VY® JPMorgan Emerging Markets Equity A
ARRRX15.63-0.04
-0.26%
AB Global Real Estate Investment R
SGMIX10.71-0.05
-0.46%
SEI Global Managed Volatility I (SIMT)

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been closely correlated with ETNB. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+1.20%
ETNB - AKRO
77%
Closely correlated
-0.48%
VTYX - AKRO
51%
Loosely correlated
-1.29%
AGEN - AKRO
39%
Loosely correlated
-2.57%
AMLX - AKRO
39%
Loosely correlated
-1.37%
INBX - AKRO
38%
Loosely correlated
-1.05%
More

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with VERA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then VERA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
+4.11%
VERA - PHAT
43%
Loosely correlated
+0.85%
TNFA - PHAT
39%
Loosely correlated
-4.68%
ATRA - PHAT
36%
Loosely correlated
-7.29%
AKRO - PHAT
32%
Poorly correlated
+1.20%
TSHA - PHAT
32%
Poorly correlated
-1.38%
More